Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17376767
Mejía-Vilet JM, et al. (2007) Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293, F78-86 17376767
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T494-p - eNOS (rat)
Modsite: TGITRKKtFKEVANA SwissProt Entrez-Gene
Orthologous residues
eNOS (human): T495‑p, eNOS (mouse): T494‑p, eNOS (rat): T494‑p, eNOS (rabbit): T501‑p, eNOS (pig): T497‑p, eNOS (cow): T497‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  kidney
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia/reperfusion no change compared to control
spironolactone decrease
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited

S1178-p - eNOS (rat)
Modsite: RIRtQsFsLQERQLR SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1179‑p, eNOS (mouse): S1178‑p, eNOS (rat): S1178‑p, eNOS (rabbit): S1185‑p, eNOS (pig): S1181‑p, eNOS (cow): S1181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  kidney
Cellular systems studied:  tissue
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia/reperfusion no change compared to control
spironolactone increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced